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Abstract 
The aim of the present study was to investigate the promoter methylation status of TRIM9 in breast cancer and to 
determine the presence of TRIM9-methylated circulating tumor DNA (ctDNA) in plasma. Bisulfite sequencing with 
a next generation sequencer showed TRIM9 promoter methylation in 92 % (11/12) of breast cancer cell lines (BCCs) 
and 68 % (13/19) of breast tumor tissues but not in any normal breast tissues (0/19). Methylation ratio of TRIM9 was 
significantly lower in basal type (9 %, n = 23) than luminal A (69 %, n = 29, P = 0.0003). Quantitative RT-PCR of BCCs 
disclosed an inverse correlation between TRIM9 mRNA expression and methylation ratio. TRIM9 methylated ctDNA in 
plasma was detected in 18 % (10/56) of metastatic breast cancer patients but not in any of 60 healthy controls. These 
results indicate that TRIM9 promoter hypermethylation, which suppresses TRIM9 mRNA expression, occurs in a sig-
nificant proportion of breast tumors, and that TRIM9-methylated ctDNA thus may serve as a tumor marker for breast 
cancer.
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Background
The promoter methylation of tumor suppressor genes is 
one of the most common events in carcinogenesis and 
has been detected in various malignant diseases includ-
ing breast cancer. Recent studies have also revealed that 
tumor-specific gene methylation can be detected in the 
circulating tumor DNA (ctDNA) of cancer patients and 
methylated ctDNA is considered to be a promising bio-
marker. Several genes including GSTP1  (Glutathione 
S-transferase P1), RASSF1A (Ras association domain fam-
ily 1A), and RARβ2 (Retinoic acid receptor β2) have been 
identified as methylated genes in breast cancer (Yama-
moto et al. 2012; Arai et al. 2006; Miyake et al. 2012) but 
each of these markers is not always specific to breast can-
cer and several markers have been used in various com-
binations. Therefore, the need has arisen for methylation 
markers which are more specific to breast cancer.
TRIM9 belongs to the TRIM (tripartite motif-containing 
protein) family which has been identified as an ubiquitin 
ligase (E3) and plays important roles in various cellular pro-
cesses (Berti et al. 2002). The TRIM family consists of over 70 
members, several of which, i.e., TRIM8, 13, 19, 24, 25, 27, 28, 
29, 31, 32, 33, 40 and 69, are known to be involved in onco-
genesis or tumor progression by affecting specific signal path-
ways such as RARα and p53 (Hatakeyama 2011). Specifically 
for breast cancers, TRIM 24, 25 and 27 have been shown to 
be significant for breast cancer prognosis, such as facilita-
tion of the ubiquitination of estrogen receptors or HER2 gene 
amplification (Hatakeyama 2011; Tsai et al. 2010; Chambon 
et al. 2011; Suzuki et al. 2005; Cao et al. 1996). TRIM9 protein 
is known as a brain-specific E3 ligase expressed in the human 
brain neurons and associated with neurological disorders 
such as Parkinson’s disease, Alzheimer’s disease, epilepsy and 
stroke (Tanji et al. 2010; Winkle et al. 2014; Shi et al. 2014). 
However, there have been no reports on possible correlation 
between TRIM9 and carcinogenesis.
Using the Illumina Human Methylation 450 database, we 
found TRIM9 is specifically methylated in breast cancer 
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tissues. The aim of the present study was therefore first 
to investigate whether methylation of TRIM9 promoter is 
associated with its gene expression in breast cancer cells, 
and second to clarify the clinicopathological characteris-
tics of TRIM9 methylated breast tumors. We analyzed the 
methylation of TRIM9 promoter by means of next genera-
tion sequencing (NGS), which yields a quantitative meth-
ylation ratio within a broad CpG area. Lastly, we examined 
whether TRIM9 methylated ctDNA can be detected in 
plasma of breast cancer patients and explored its utility as 
a novel blood biomarker for breast cancer diagnosis.
Methods
Extraction of targeted gene
We used a common methylation database, Illumina 
Human Methylation 450, provided by the Cancer 
Genome Atlas (TCGA) Data Portal, National Cancer 
Institute, Washington, D.C., USA (http://cancergenome.
nih.gov/) to find 90 cases which included methylation 





Type=42). We downloaded the β-score calculated from 
about 485,000 CpG sites of 90 paired cancerous and non-
cancerous breast tissues, and 547 probes met all of three 
criteria for inclusion in our study, that is, methylation 
ratio in cancer tissues >45  %, methylation ratio in nor-
mal tissues <5 %, and area under the ROC curve >0.85. 
Next, we used the t test to compare the methylation sta-
tus of breast cancer and other cancers. Finally, ten probes 
showing the highest methylation ratio specific to breast 
cancers qualified as candidates, and among these we 
decided to target TRIM9, since this was the only probe as 
yet not known to be associated with breast cancers.
Patients and breast tumor samples
Study I
Nineteen pairs of tumor tissues and normal tissues were 
obtained at surgery between 2001 and 2004 from primary 
breast cancer patients who had received no preoperative 
chemotherapy or hormonal therapy. The clinicopatholog-
ical characteristics of these patients are summarized in 
Additional file 1: Table S1. Normal tissues were obtained 
from a quadrant other than the one harboring cancer. 
Tissue samples were snap frozen in liquid nitrogen and 
kept at −80 °C until use.
Study II
Stage II or III primary breast cancer patients (n = 107), 
who had been treated with neoadjuvant chemotherapy 
(NAC) consisting of paclitaxel (80 mg/m2) weekly for 12 
cycles followed by 5-FU (500 mg/m2), epirubicin (75 mg/
m2) and cyclophosphamide (500  mg/m2) every 3  weeks 
for four cycles at Osaka University Hospital between 
2004 and 2009, were retrospectively included in this 
study. Each patient underwent vacuum assisted biopsy 
(VAB) of the tumors, and the tumor samples were snap 
frozen in liquid nitrogen and kept at −80  °C until use. 
Histological grade, ER, PR, and HER2 status were deter-
mined as described in a previous report of ours (Miyake 
et al. 2012). Ki67 was classified as “high” when ≥20 % of 
tumor cells were immunohistochemically positive (clone; 
MIB-1). Pathological complete response (pCR) was 
defined as no evidence of invasive cancer components 
in breast irrespective of any axilla lymph nodes metas-
tases. Intrinsic subtypes were determined by means of 
DNA microarray using the PAM50 method as previously 
described (Naoi et al. 2011; Parker et al. 2009). The clin-
icopathological characteristics of these patients are sum-
marized in Table 1. These studies were approved by the 
Ethical Review Board of Osaka University Hospital and 
the Research Ethics Committee of Osaka University, and 
informed consent was obtained from each patient before 
sampling.
DNA extraction and sodium bisulfite treatment
Total DNA from cell lines was isolated using TRIzol® 
reagent (Invitrogen, Carlsbad, CA, USA) and total DNA 
from the breast tissues was extracted using the DNeasy® 
Blood and Tissue Kit (QIAGEN, Valencia, CA, USA). 
1  μg of genomic DNA was then subjected to sodium 
bisulfite treatment with the EpiTect® Bisulfite Kit (QIA-
GEN), and the QIAamp® Circulating Nucleic Acid Kit 
(QIAGEN) was used to extract plasma DNA from a 2 ml 
plasma sample, which was then subjected to sodium 
bisulfite treatment as previously described (Fujita et  al. 
2012).
Quantitative TRIM9 promoter methylation analysis using 
NGS
The NGS methylation assay was performed with the GS 
Junior system (Roche Diagnostics, Basel, Switzerland) 
according to the manufacturer’s instructions, and data 
was analyzed with GS Amplicon Variant Analyzer (AVA) 
software (version 2.7; Roche Diagnostics). The methyla-
tion index (MI) was calculated by dividing the number 
of cytosines by that of the total reads at each CpG site. 
NGS primers used for TRIM9 methylation of frozen 
tissues or cell lines were designed as follows: forward 
5′-TGTTTGGAGTGAAATATTGAGATTT-3′, reverse 
5′-ACAATAAAACTTTTCTCCTTCTCC-3′ (long 
primer; Fig. 1). The average methylation ratio of 12 of the 
26 CpG sites (6th–17th CpG), which showed the most 
significant difference between cancer and normal tissues, 
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was used for methylation analysis. NGS primers used 
for DNA from formalin-fixed paraffin embedded (FFPE) 
specimens were designed as follows: forward 5′-AGTT-
TAGTTAGGTGTTTTGGGAGGT-3′, reverse 5′-ACAT-
TAATCAAAATCTATAACCCCTTC-3′ (short primer; 
Fig. 1). The NGS short primer included 7 CpG sites, cor-
responding to 6th–12th CpG.
In situ hybridization (ISH) for TRIM9 mRNA 
and immunohistochemical staining (IHC) for TRIM9 protein
The QuantiGene®ViewRNA ISH Tissue Assay kit (Affy-
metrix, Santa Clara, CA, USA) was used according to the 
manufacturer’s protocol. FFPE Sections (4 μm) of tumor 
tissues were incubated at 98  °C with a pretreatment 
solution for 20  min, followed by protease digestion for 
10 min. The TRIM9-specific View RNA™ Probe set (Affy-
metrix) was hybridized for 2 h. A TRIM9 specific probe 
set was then designed to hybridize the common sequence 
of TRIM9_v1 and TRIM9_v2 (1319 bp). ISH images were 
obtained under fluorescent microscopy (BZ9000; Key-
ence, Osaka, Japan). Signal intensity was semi-quantita-
tively determined based on the number of cytoplasmic 
fluorescent dots in five non-overlapping fields at high-
power magnification (×400).
Formalin-fixed paraffin Sections  (3  μm) of the tumor 
tissues were obtained for immunohistochemical stain-
ing with rabbit anti-TRIM9 polyclonal antibody (Pro-
teinTech Group, Inc., Chicago, IL, USA) at a dilution of 
1:400 according to a previously described method for ER, 
PR and Ki-67, with a slight modification in that antigen 
retrieval was accomplished by incubating at 98 °C in cit-
rate buffer (pH 9.0) for 40 min (Shimomura et  al. 2009; 
Table 1 Comparison of TRIM9 methylation ratio with vari-
ous clinicopathological parameters of breast tumors
Characteristics Total TRIM9
Methylation ratio mean ± SE P value*
All cases 107
 Age (years)
  <50 49 11.2 ± 1.54 0.052
  ≥50 58 7.44 ± 1.10
 Menopausal status
  Pre 51 10.7 ± 1.51 0.117
  Post 56 7.73 ± 1.14
 Tumor size
  T1+2 84 8.97 ± 1.04 0.709
  T3+4 23 9.83 ± 2.19
 Lymph node metastasis
  Negative 30 10.9 ± 2.27 0.338
  Positive 77 8.48 ± 0.96
 Stage
  II 88 9.02 ± 1.02 0.768
  III 19 9.75 ± 2.50
 Histological type
  IDC 97 8.66 ± 0.99 0.104
  ILC 10 13.9 ± 2.68
 Estrogen receptor
  Negative 42 3.47 ± 0.56 <0.0001
  Positive 65 12.8 ± 1.32
 Progesterone receptor
  Negative 65 6.93 ± 1.01 0.005
  Positive 42 12.6 ± 1.70
 HER2 receptor
  Negative 76 9.07 ± 1.10 0.893
  Positive 31 9.35 ± 1.85
 TNBC
  No 82 11.2 ± 1.13 <0.0001
  Yes 25 2.39 ± 0.32
 Subtype (IHC)
  LumA 51 12.3 ± 1.42 <0.0001
  LumB 14 14.6 ± 3.40
  HER2 17 5.06 ± 1.21
  TN 25 2.39 ± 0.32
 Subtype (PAM50)
  LumA 29 13.7 ± 1.89 <0.0001
  LumB 21 10.1 ± 2.24
  HER2 16 9.90 ± 2.65
  Basal-like 23 3.22 ± 0.84
  Normal-like 18 7.70 ± 2.24
 Histological grade
  1+2 86 9.89 ± 1.09 0.112
  3 21 6.12 ± 1.64
 Ki67




Methylation ratio mean ± SE P value*
  High (≥20 %) 62 8.43 ± 1.33
  Unknown 1
 Clinical response
  No CR 70 8.62 ± 1.13 0.434
  CR 37 10.2 ± 1.70
 Histological response
  Grade 1, 2a 58 11.4 ± 1.37 0.006
  Grade 2b, 3 49 6.45 ± 1.17
 Pathological response
  No pCR 74 11.0 ± 1.20 0.001
  Pcr 33 5.02 ± 1.15
 Recurrence
  No 90 9.88 ± 1.08 0.007
  Yes 17 5.30 ± 1.12
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Tanei et  al. 2009). Immunohistochemical staining for 
TRIM9 was classified as 3+ (strongly positive), 2+ (inter-
mediately positive), 1+ (weakly positive) or 0 (negative). 
The sections were counterstained with hematoxylin.
Isolation of breast tumor cells by magnetic‑activated cell 
sorting (MACS)
Breast tumor cells were separated from the FFPE tumor 
tissues with the magnetic-activated cell sorting (MACS) 
method using the EasySep Human EpCAM Positive 
Selection Cocktail, the EasySep Human MUC1 Positive 
Selection Cocktail and EasySep Magnetic Particles (Stem 
Cell Technologies, Vancouver, BC, Canada) as previously 
described (Otani et  al. 2014). Total DNA was extracted 
from these isolated tumor cells using the QIAamp® DNA 
FFPE Tissue Kit (QIAGEN).
Demethylation study of cell lines using 
5‑aza‑2′‑deoxycytidine
Twelve breast cancer cell lines (BCCs) and one normal 
breast cell line were cultured under the conditions shown 
in Additional file 2: Table S2. For demethylation studies, 
the cultured cells were treated with 10  μmol/L 5-aza-
2′-deoxycytidine (5-aza; Sigma-Aldrich, St Louis, MO, 
USA) or with dimethylsulfoxide (DMSO) as control for 
72 h, with the medium changed every 24 h.
RNA extraction and real‑time qRT‑PCR
Total RNA was isolated from cell lines using TRIzol® 
reagent (Invitrogen), and 1 μg of total RNA was reverse-
transcribed for single strand cDNA, using random prim-
ers and the ReverTra Ace® qPCR RT kit (Toyobo, Osaka, 
Japan). Reverse-transcription reaction was performed 
first at 65 °C for 5 min and then at 37 °C for 15 min and 
at 98  °C for 5  min. Quantitative mRNA expression was 
measured using the Light Cycler 480 Real-time PCR 
System (Roche Applied Science, Mannheim, Germany) 
at 95  °C (10  min), followed by 50 cycles at 95  °C (15  s) 
and at 60  °C (60  s), and 1 cycle at 50  °C (10  s). TRIM9 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
TaqMan® Gene Expression Assays (assay identification 
numbers: Hs00364838_m1 and Hs02758991_g1. Applied 
Biosystems, Foster City, CA, USA) were used for the real 
time qPCR assay. The expression of TRIM9 was normal-
ized to that of GAPDH, and each assay was performed in 
duplicate. For the 5-aza treated BCCs, each treated cell 
line was normalized to the value of its control, which was 
set at 1.
Fig. 1 Primer designs for DNA methylation analysis of TRIM9 using NGS and for detection of TRIM9 methylated ctDNA using real-time PCR. Long 
primer sets were designed for DNA methylation analysis of TRIM9 by means of NGS (solid arrow). TRIM9 methylated ctDNA in plasma was detected 
by means of real-time PCR using the short primers (dashed arrow) and probes (dotted line)
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Measurement of TRIM9 methylated ctDNA in plasma
Two ml of plasma samples was obtained from healthy 
controls (n  =  60) and from metastatic breast cancer 
(MBC) patients (n  =  56), 41 cases of recurrent and 15 
of primary advanced breast cancer, before they had been 
treated at Osaka Police Hospital or Osaka University 
Hospital between 2012 and 2014. TRIM9 methylated 
ctDNA in plasma was measured by using quantitative 
methylation-specific PCR (MSP) with the TRIM9 short 
primer (Fig. 1). The double-dye probe, including TRIM9 
8th–10th CpG sites (5′-TCGTGGAAGGAAGTACGTT-
TATATTAC-3′; Fig.  1) for detection of TRIM9 methyl-
ated ctDNA in plasma, is shown in Fig.  1. 9  µl aliquot 
each of the bisulfite DNA, eluted for a total PCR reac-
tion volume of 20  µl, was placed in 96-well plates for 
the TRIM9 PCR reactions. TRIM9 methylated ctDNA 
in plasma was classified as positive when quantification 
cycles were less than 50 cycles for TRIM9.
Statistical analysis
The JMP statistical software package (version 11.2.1; SAS 
Institute, Cary, NC, USA) was used for statistical analy-
ses. Association between the various parameters and 
TRIM9 methylation ratio was evaluated using the t test 
for two groups or the Kruskal–Wallis test for more than 
two groups. The paired t test was used for comparison 
of frozen cancer and normal tissue MI in matched-pair 
samples. The Tukey test was used for comparison of the 
TRIM9 methylation ratio for each subtype. The uni-
variate and multivariate analysis of various parameters 
for the association with pCR were performed with the 
logistic regression model. All statistical analyses were 
two-sided and P values <0.05 were considered to be sta-
tistically significant.
Results
Promoter methylation of TRIM9 and its impact on gene 
expression in BCCs
To study the methylation status of TRIM9, we performed 
an NGS methylation assay of the TRIM9 promoter in 12 
BCCs and a normal breast cell line (HMEC). The meth-
ylation ratio of the TRIM9 gene promoter varied greatly 
from 10.3 to 92.6 % in 11 of the BCCs and was relatively 
hypomethylated in the HMEC cells (Fig.  2a; Additional 
file 3: Table S3).
We next used TRIM9-specific primers and probes to 
investigate the TRIM9 mRNA expression by qRT-PCR. 
An inverse correlation between the TRIM9 mRNA 
expression and methylation ratio was clearly observed 
(Pearson’s correlation coefficient: −0.753) (Fig.  2a). We 
then treated eight of these cell lines with a demethylat-
ing reagent (10  μM 5-aza) and compared the mRNA 
expression of the treated and untreated cells. 5-aza treat-
ment induced a 16- to 110-fold up-regulation of mRNA 
expression in all four hypermethylated BCCs (MDA-
MB-453, BT474, SKBR3 and MDA-MB-361), while 
no up-regulation was detected in any of the four hypo-
methylated BCCs (MDA-MB-468, ZR75-30, T47D and 
MDA-MB-231), demonstrating that the TRIM9 gene was 
re-expressed by the demethylation of its promoter region 
(Fig. 2b).
Methylation and expression of TRIM9 in human breast 
cancer tissues
To study the methylation status of TRIM9 in human 
breast cancer and normal breast tissues, we performed 
an NGS methylation assay using the 19 paired tumor 
and normal tissues (study I). The methylation ratio 
was significantly higher for the tumor tissues than the 
Fig. 2 TRIM9 methylation status and mRNA expression of 13 breast cancer cell lines. a Correlation between TRIM9 methylation index and mRNA 
expression. b Fold changes in TRIM9 mRNA expression of 8 cell lines after 5-aza treatment
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normal tissues (median values, 19 and 1.8 %, respectively, 
P = 0.00067; Fig. 3a). The ratio of TRIM9 hypermethyl-
ated tumors (methylation ratio ≥8.2 %) was 68 %.
For a more accurate assessment of the cancer cell-spe-
cific methylation status, we isolated the tumor cells from 
the FFPE tumor tissues with the MACS method, and 
the isolated tumor cells were then subjected to an NGS 
methylation assay. Five tumor tissues with a low meth-
ylation ratio (<25  %) were further analyzed since it was 
thought the low methylation ratio of some of them was 
due to contamination by the normal stromal and inflam-
matory cells. Methylation ratios increased in the tumor 
cells isolated from whole tumor tissues (Fig. 3b).
Relationship between TRIM9 methylation 
and clinicopathological characteristics
An NGS methylation assay of TRIM9 was performed 
using the biopsy specimens obtained before NAC (study 
II) to examine the relationship between TRIM9 meth-
ylation and the various clinicopathological parameters 
including response to NAC (Table 1). TRIM9 hypermeth-
ylation (methylation ratio ≥8.2 %) was observed in 40 % 
(43/107) of the specimens. TRIM9 hypermethylation was 
significantly associated with ER positivity, PR positivity, 
low histological grade and no pCR (Table 1). Furthermore, 
the methylation ratio was significantly lower for basal type 
(9 %) than for luminal A type (P = 0.0007; Fig. 4).
Next, to determine whether methylation is related to 
gene expression, we subjected the TRIM9 hypermethyl-
ated (n  =  10) and hypomethylated tumors (n  =  10) to 
ISH and IHC and found that neither ISH signals nor IHC 
scores in tumor cells were significantly associated with 
methylation ratios (Fig. 5).
Relationship between TRIM9 methylation and response 
to NAC
The clinicopathological parameters were assessed by 
means of univariate analysis for their association with 
pCR (Table  2). Age, Ki67, ER, PR, HER2, and TRIM9 
methylation were found to be significantly associated 
with pCR. The multivariate analysis showed that only ER, 
but not TRIM9 methylation, was a significant and inde-
pendent predictor for pCR.
Detection of TRIM9‑methylated ctDNA in MBC patients
TRIM9-methylated ctDNA in plasma of 56 MBC patients 
and 60 healthy controls was assayed by using MSP. An 
amplification curve of the eight standards was obtained 
by diluting the methylated human control DNA (diluted 
to 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0 ng/ml plasma). The 
limit of detection for methylated TRIM9 DNA was 
0.1  ng/ml in plasma. TRIM9 methylated ctDNA was 
detected in 18 % (10/56) of MBC patients but not in any 
of the healthy controls. Primary breast tumor tissues for 
determination of TRIM9 methylation status were avail-
able for 27 of the 56 cancer patients, and TRIM9 meth-
ylated ctDNA was detected in 44  % (4/9) of the MBC 
patients with TRIM9 hypermethylated tumors but in 























































Fig. 3 Methylation status of TRIM9 in breast cancer and normal breast tissues. a Comparison of TRIM9 methylation index for 19 paired normal breast 
and cancer tissues. b Comparison of TRIM9 methylation index for whole breast cancer tissues and tumor cells isolated with the MACS method
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Discussion
For this study, we selected the TRIM9 gene as a breast 
cancer specific methylation marker by referring to the 
methylation array database and observed TRIM9 hyper-
methylation in 92 % (11/12) of the BCCs and 68 % (13/19) 
of breast tumor tissues but not in any of the normal 
breast epithelial cell line (HMEC) cells or normal breast 
tissues. Several methylation markers for breast can-
cers have been investigated, such as GSTP1, RASSF1A 
and RARβ2, and hypermethylation of these genes has 
been reported as, respectively, 17–48  %, 43–90  % and 
26–78  % in breast cancer tissues and as 2–3  %, 3–8  % 
and 0 % in normal breast tissues (Yamamoto et al. 2012; 
Jung et  al. 2013; Hagrass et  al. 2014; Pirouzpanah et  al. 
2015), indicating the equally high sensitivity and specific-
ity of TRIM9 as a methylation marker for breast cancer. 
Although methylation of these other genes has report-
edly been detected in other types of cancers than breast 
Fig. 4 Methylation status of TRIM9 in 107 breast cancer tissues. Breast 
tumors were classified into five intrinsic subtypes (luminal A, luminal 
B, HER2, basal-like, normal breast-like) by PAM50 for comparison of 
their methylation index of TRIM9. *Tukey’s test
Fig. 5 Association between TRIM9 mRNA expressions obtained with ISH and IHC analysis and methylation ratios in breast cancer tissues. TRIM9 
hypermethylated or hypomethylated breast cancer tissues were subjected to ISH (a) and IHC (b) for TRIM9 mRNA. Each immunoreactivity was one 
of four scores (0, 1+, 2+ and 3+). ISH, in situ hybridization; IHC, immunohistochemistry
Table 2 Univariate and multivariate analysis of clinicopathological factors for pCR
CI confidence interval
Characteristics Univariate analysis Multivariate analysis
Odds ratio 95 % CI P value Odds ratio 95 % CI P value
Age (≥50 vs <50) 3.13 1.29–7.66 0.0091 2.24 0.80-6.56 0.1236
T stage (T1+2 vs T3+4) 1.80 0.61–5.35 0.2743
Lymph node status (positive vs negative) 1.68 0.64–4.41 0.2858
ER (negative vs positive) 10.5 4.00–27.4 <0.0001 5.14 1.23–27.2 0.0240
PgR (negative vs positive) 5.60 1.95–16.1 0.0004 0.98 0.17–4.86 0.9823
HER2 (positive vs negative) 2.47 1.03–5.94 0.0440 1.98 0.69–5.76 0.2002
TRIM9 methylation (<8.2 vs ≥8.2 %) 10.6 2.96–37.6 <0.0001 3.96 0.97–20.1 0.0545
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cancer (Zhang et al. 2015; Li et al. 2015a, b; Grote et al. 
2005), TRIM9 is methylated specifically in breast can-
cer according to the Illumina Human Methylation 450 
database (http://cancergenome.nih.gov/), implying that 
TRIM9 may function as a methylation marker that is 
specific to breast cancer. The fact that the methylation 
ratio was lower in tumor tissues than BCCs seems to be 
explained by the contamination of tumor tissues by the 
normal stromal and inflammatory cells, since the tumor 
cells isolated by MACS showed an evidently higher 
methylation ratio than the tumor tissues from which they 
derived. These results indicate that breast tumor cells, 
but not normal breast epithelia, actually harbor TRIM9 
methylation.
We found that TRIM9 mRNA expression correlated 
inversely with TRIM9 methylation ratio in BCCs, and 
that treatment of TRIM9 hypermethylated BCCs with 
a demethylating reagent resulted in the reactivation of 
TRIM9 mRNA expression. Although these findings sug-
gest that TRIM9 expression is epigenetically regulated 
by promoter methylation in BCCs, we could not con-
firm the occurrence of such an epigenetic regulation in 
breast tumor tissues. No reports have been published so 
far on possible associations between promoter methyla-
tion and gene expression in the TRIM family, including 
TRIM9. TRIM9 is known to be up-regulated by interfer-
ons, suggesting that another mechanism than promoter 
methylation may be more important in the regulation 
of gene expression in breast cancer tissues (Carthagena 
et al. 2009) although promoter methylation seems to play 
a significant role in vitro as we have shown in the present 
study.
The TRIM9 methylation ratio was significantly lower 
in basal type tumor than in the other intrinsic sub-
types, which is consistent with the report that basal 
type tumors are more globally hypomethylated than the 
other subtypes (Cancer Genome Atlas Network 2012). 
Although TRIM9 hypermethylation was found to be 
significantly associated with no pCR, this does not 
necessarily mean that TRIM9 hypermethylation plays 
a significant role in resistance to chemotherapy. Mul-
tivariate analysis failed to demonstrate any statistical 
significance for TRIM9 hypermethylation as an inde-
pendent predictor for no pCR. It is thus speculated that 
TRIM9 hypermethylation may be indirectly associated 
with no pCR via its strong association with ER, which 
is a well-established predictor for no pCR (Carey et al. 
2007; Rouzier et al. 2005; Ignatiadis and Sotiriou 2013). 
Putting these considerations together suggests that 
TRIM9 is unlikely to play a significant role in chemo-
therapy resistance or is at least, not a clinically useful 
predictor for no pCR.
Our study detected TRIM9 methylated ctDNA in 
only 18  % (10/56) of MBC patients. However, this 
sensitivity was as high as 44  % (4/9) when only the 
MBC patients with TRIM9 methylated tumors were 
taken into consideration, but it was only 5.6 % (1/18) 
for those without TRIM9 methylated tumors. Pre-
vious studies have reported that aberrant promoter 
methylation in serum DNA of MBC patients was 
18–25  % for GSTP1 (Yamamoto et  al. 2012; Müller 
et al. 2003; Sharma et al. 2010), 33–39 % for RASSF1A 
(Yamamoto et  al. 2012; Müller et  al. 2003; Kim et  al. 
2010) and 20–87  % for RARβ2 (Yamamoto et  al. 
2012; Sharma et  al. 2010; Kim et  al. 2010). Although 
methylated TRIM9 in blood was less sensitive than 
the existing methylation markers, the specificity was 
100  % which was superior to that of any other genes 
(2–10  % for GSTP1, 0–10  % for RASSF1A and 5–6  % 
for RARβ2) (Yamamoto et al. 2012; Müller et al. 2003; 
Kim et al. 2010). TRIM9-methylated ctDNA may thus 
be a potential tumor marker and might work better in 
combination with other blood biomarkers for breast 
cancers to compensate for its lower sensitivity. How-
ever, the number of patients in our study was limited 
and further prospective studies are needed to verify 
our findings.
Conclusions
We found that TRIM9 promoter hypermethylation 
occurred in 68  % of breast tumors but not in normal 
breast tissues. Methylated TRIM9 was detected in the 
plasma from 44  % of metastatic breast cancer patients 
with TRIM9 methylated tumors. Although the regulatory 
mechanism of TRIM9 gene expression and its biological 
functions remain unclear, our preliminary results suggest 
that methylated TRIM9 may serve as a novel blood bio-
marker specific to breast cancer patients.
Table 3 Sensitivity for  detection of  methylated TRIM9 
in  plasma of  Stage IV and  metastatic breast cancer 
patients
MBC metastatic breast cancer
Total Methylated TRIM9 in plasma
Positive Negative
No. (%) No. (%)
Healthy control 60 0 (0) 60 (100)
MBC patients (total) 56 10 (18) 46 (82)
MBC patients with TRIM9 
hypermethylated tumors
9 4 (44) 5 (56)
MBC patients with TRIM9 
hypomethylated tumors
18 1 (6) 17 (94)
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